Cipla Ltd is a renowned pharmaceutical company known for its strong values and corporate philosophy. Founded on the principles of excellence, integrity, and social responsibility, Cipla is dedicated to providing affordable and high-quality healthcare solutions to people across the globe. The company's philosophy revolves around ensuring access to life-saving medications, innovation, and continuous improvement. Cipla's commitment to ethical business practices, customer-centric approach, and sustainable development has garnered them a strong reputation in the industry. With a focus on the well-being of patients and the community, Cipla Ltd remains at the forefront of the pharmaceutical sector, upholding its core values in every aspect of its operations.

Cipla Ltd is primarily present in various countries and regions worldwide. As an Indian multinational pharmaceutical company, Cipla has a significant presence not only in India but also in other key markets. Its operations extend to Africa, including South Africa, Kenya, Uganda, and Nigeria, where it has established a strong foothold. Cipla also has a substantial presence in the United States and Europe, catering to the healthcare needs of patients in these regions. Additionally, Cipla has expanded its footprint across Asia, including countries like Bangladesh, Sri Lanka, and Myanmar, among others, serving diverse populations with its range of high-quality pharmaceutical products.

Cipla Ltd has achieved several significant milestones throughout its history. The pharmaceutical company has expanded its global presence by establishing a strong foothold in more than 80 countries. Cipla has played a crucial role in improving access to affordable medicines, especially for life-threatening diseases like HIV/AIDS. The company has been recognized for its efforts in developing innovative and cost-effective pharmaceutical products. Cipla has also received several accolades and certifications for its quality control and manufacturing processes, ensuring the highest standards of drug production. With a dedicated focus on research and development, Cipla continues to strive for excellence in providing healthcare solutions worldwide.

Cipla Ltd, a renowned pharmaceutical company, has a rich history and background. Founded in 1935, Cipla has become a global leader in providing affordable and accessible medicines. With a strong focus on innovation and quality, Cipla has revolutionized the pharmaceutical industry. The company has played a vital role in bringing life-saving drugs to the market, including those for HIV/AIDS and cancer treatment. Cipla's commitment to social causes is evident through its initiatives to provide affordable healthcare to underprivileged communities. Over the years, Cipla has earned a reputation for its ethical practices, cutting-edge research, and dedication to improving global healthcare.

The main competitors of Cipla Ltd in the market are leading pharmaceutical companies such as Sun Pharmaceutical Industries Ltd, Lupin Limited, Dr. Reddy's Laboratories Ltd, and Cadila Healthcare Ltd. These companies compete with Cipla in areas such as generic drugs, branded pharmaceuticals, and focus on various therapeutic categories. Cipla Ltd faces stiff competition from these prominent players in the industry, as they strive to capture market share, enhance product portfolios, and expand their global presence.

Cipla Ltd is primarily active in the pharmaceutical industry.

Cipla Ltd is a leading pharmaceutical company based in India. Its business model focuses on research, development, manufacturing, and marketing of a wide range of healthcare products. With a commitment to accessible healthcare, Cipla offers affordable medications, including generic drugs, to patients globally. The company's extensive product portfolio includes prescription drugs, over-the-counter medications, diagnostics, and various therapies. Cipla operates through multiple business segments, including pharmaceuticals, New Ventures, and consumer healthcare. By leveraging its robust research capabilities and strong marketing network, Cipla continues to strive towards enhancing the quality of life and ensuring better healthcare outcomes for individuals worldwide.

Το Cipla P/E είναι 22,72.

Το KUV της εταιρείας Cipla είναι 4,35.

Το AlleAktien Qualitätsscore για το Cipla είναι 9/10.

Ο κύκλος εργασιών του Cipla είναι 275,48 δισ. INR.

Το Cipla κέρδος είναι 52,73 δισ. INR.

The Indian pharmaceutical company Cipla Ltd has been active in the industry for over 80 years and specializes in the development, manufacture, and distribution of generic drugs. The company is headquartered in Mumbai and operates in over 80 countries. Cipla is one of the leading companies in the generic drug industry and offers a wide range of products in various therapeutic areas. One of Cipla's main areas is the production of medications for the treatment of respiratory diseases such as asthma and COPD. The company develops and manufactures both inhalers and tablets and syrups. Cipla is also active in other areas such as oncology, HIV/AIDS, diabetes, and cardiovascular diseases, and offers a broad range of products. Cipla also has a division for biosimilars, which are products that are similar in structure to biological drugs but come from a different manufacturer. Biosimilars are a growing area in the pharmaceutical industry as they can have higher efficacy and fewer side effects than conventional drugs. The company also has partnerships with international pharmaceutical companies such as Roche and Gilead Sciences to distribute their products in India and other countries. Cipla also has a strong presence on the African continent, where it operates in 54 countries and focuses on providing healthcare services, especially in rural areas. Cipla has state-of-the-art manufacturing facilities that comply with the highest international quality standards. These facilities are located in India, South Africa, Uganda, and other countries. The company also conducts research and development activities to develop new products and expand its product range. The company has filed several patents and works closely with global stakeholders to develop innovative solutions to health problems. In addition to its business activities, Cipla is also committed to social responsibility and promotes the health and well-being of people in rural areas and disadvantaged communities. The company also supports various non-profit organizations and participates in philanthropic activities. Overall, Cipla's business model focuses on promoting affordable and high-quality healthcare worldwide. To do this, the company leverages its expertise in the development and production of generic drugs and biosimilar products, as well as its partnerships with other global pharmaceutical companies. Cipla has a strong presence in emerging markets and is committed to improving the health and well-being of people around the world.

Η Cipla καταβάλλει μια διανομή της τάξεως των 5,00 INR διαμοιρασμένη σε δόσεις ετησίως.

Το μέρισμα δεν μπορεί να υπολογιστεί για το Cipla αυτή τη στιγμή ή η εταιρεία δεν διανέμει μέρισμα.

Ο αριθμός ISIN της Cipla είναι INE059A01026.

Ο τίκερ της Cipla είναι CIPLA.NS.

Κατά τους τελευταίους 12 μήνες η Cipla κατέβαλε μια μέρισμα ύψους 3,00 INR . Αυτό αντιστοιχεί σε απόδοση μερίσματος περίπου 0,20 %. Για τους επόμενους 12 μήνες, η Cipla προβλέπεται να πληρώσει μέρισμα 3,31 INR.

Η απόδοση μερίσματος της Cipla ανέρχεται σήμερα στο 0,20 %.

Cipla πληρώνει τέταρτον διανεμητέου μισθό. Αυτή καταβάλλεται τους μήνες Σεπτεμβρίου, Αυγούστου, Σεπτεμβρίου, Ιουλίου.

Η Cipla πλήρωσε κάθε χρόνο μέρισμα μέσα στα τελευταία 23 έτη.

Για τους επόμενους 12 μήνες αναμένονται μερίσματα σε ύψος των 3,31 INR. Αυτό αντιστοιχεί σε απόδοση μερίσματος 0,22 %.

Το Cipla ανατίθεται στον τομέα 'Υγεία'.

Για να λάβεις το τελευταίο μέρισμα των Cipla από την 15/8/2025 με τιμή 3 INR, έπρεπε να έχεις τη μετοχή στο χαρτοφυλάκιο σου πριν από την ημέρα Ex-Tag στις 27/6/2025.

Η τελευταία μερίσματος έγινε στις 15/8/2025.

Το έτος 2024, η Cipla διένειμε 13 INR ως μερίσματα.

Τα μερίσματα του Cipla καταβάλλονται σε INR.